Lab21 announces sale of South Carolina Operations

14-Jan-2013 - Lab21 Limited announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors. In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making ...

Lab21 launches new lung cancer companion diagnostic service

20-Feb-2012 - Lab21 Limited has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients.The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test uses ...

Lab21 Wins Biomedical Project of the Year Award

01-Dec-2011 - Lab21 Limited has won the BioNow Biomedical Project of the Year Award for its MycAssay product line. The BioNow Biomedical Project of the Year Award recognises individuals or organisations who have demonstrated an innovative solution to a specific industry problem. Lab21’s MycAssay Aspergillus ...

Lab21 acquires molecular diagnostics company Myconostica Ltd

25-May-2011 - Lab21 Limited has announced that it has acquired Myconostica Ltd. The financial terms of the deal were not disclosed. The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays. Furthermore it will ...

Lab21 acquires Microgen Bioproducts

10-Jan-2011 - Lab21 Limited announced that it has acquired Microgen Bioproducts Ltd a UK company specialising in the development, manufacture and sale of diagnostic tests to identify diseases and organisms which pose a threat to health. Microgen Bioproducts’ expertise in microbiological assay development and ...

Lab21 expands its range of cardiovascular genetic tests with Clinical Data, Inc.

29-Sep-2008 - Lab21 announced the expansion of its portfolio of genetic tests for inherited cardiac syndromes. Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc., Lab21 offers exclusive U.K. and Ireland access to the Familion® portfolio of tests for Long QT and Brugada ...

Predictive genetic test for bowel cancer treatment is introduced in the UK

Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test

20-Mar-2008 - Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for ...

Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

25-Feb-2008 - Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of ...

Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic

15-Oct-2007 - Lab 21 announced that it has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidized low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart disease (CHD). The oxLDL test can identify ...

Lab21 - a new kind of company

Antiviral drug discovery services and clinical trials support

18-Jul-2005 - A new company - Lab21 - has been launched to provide technically advanced drug discovery and clinical trials services to the pharmaceutical and biotech industries. Testing is performed in state-of-the-art laboratories in Cambridge (UK), with commercial headquarters in Fareham (UK). Lab21 ...